News & HighlightsNews
Newly discovered anti-CRISPR protein gives viruses a leg up against bacteria
Molecular CRISPR-Cas systems, most commonly known for their usefulness as gene editing tools, are ancient defense mechanisms employed by bacteria against viruses. The discovery of a counteracting viral trick could inform scientists' efforts to develop future gene-editing technologies.
Will SARS-CoV-2 escape future drugs by mutating? The answer may be a nuanced “no.”

Scientists hope to deploy antibodies in the quest to end COVID-19. A recent study moves them closer to accomplishing a key step: finding out if the virus may acquire resistance to antibody-based drugs or vaccines, and how to potent...

How toothless mock viruses could advance research on COVID-19
Scientists have engineered four viruses resembling SARS-CoV-2 to enable faster and safer research on vaccines and treatments.
COVID-19 immunology study reveals universally effective antibodies

New findings characterize human antibody response to SARS-Cov-2, with implications for convalescent plasma therapy, vaccine design, and antibody-based drugs.

How antibodies from llamas may lead to COVID-19 treatment
Llamas make antibodies that are much smaller than their human counterparts, yet still potent. Scientists hope that future drugs based on these molecules could provide new weapons against SARS-CoV-2.
Study reveals first evidence inherited genetics can drive cancer’s spread
Scientists have long struggled to understand what drives a tumor to seed itself elsewhere in the body. New research implicates our own pre-existing genetics.
Rockefeller scientists investigate life-threatening inflammation affecting children with COVID-19
The condition resembles a rare childhood illness, Kawasaki disease. Researchers are analyzing blood samples to find genetic clues to what might be causing it.
The gene hunt to explain why some young, healthy people die from COVID-19
People under 50 without preexisting conditions typically develop mild symptoms of coronavirus infection—but there are exceptions. Researchers are working to identify rare genetic variations that may explain why some in this group have succumbed to the disease.
Scientists are using ‘elite’ antibodies from COVID-19 survivors to develop potent therapies

Most people infected with the coronavirus are able to fight it off because their immune system produces effective antibodies. Rockefeller scientists are working to turn such antibodies into a drug.

Rockefeller scientists launch a broad range of studies into novel coronavirus
Over 130 scientists in 18 labs are conducting research to advance the development of new, urgently needed approaches for the prevention and treatment of COVID-19.
View
View